2Seventy Bio

Price & Volume

Track all markets on TradingView

Stats

See more
Open
$2.50
Previous Close
$2.45
Day Range
$2.43-$2.55
52W Range
$2.34-$6.40
Market Cap
$134.6M
Shares Short
4M

Financials

See more
Revenue (12 Mos)
$45.6M
Revenue Growth (YoY)
12.5%
Gross Profit (12 Mos)
-$90.7M
Diluted EPS
-$1.83

News

See more

Yahoo Finance • 12 months ago

Bristol Myers Squibb and 2seventy bio Share Update on U.S. FDA Oncologic Drugs Advisory Committee Meeting for Abecma in Triple-Class Exposed Multiple Myeloma Based on KarMMa-3 Study

Yahoo Finance • last year

Abecma Delivers Sustained Progression-Free Survival Versus Standard Regimens in Earlier Lines of Therapy for Relapsed and Refractory Multiple Myeloma Based on Longer-Term Follow-up from KarMMa-3

Yahoo Finance • last year

10 Stocks That Are About To Explode

Yahoo Finance • 2 years ago

Regulatory Applications Accepted Across Three Regions Globally for Abecma for Earlier Use in Adults with Triple-Class Exposed Relapsed and/or Refractory Multiple Myeloma

About

CEO
Mr. William D. Baird III, M.B.A.
Address
60 Binney Street, Cambridge, MA, United States, 02142
Sector
Healthcare
Industry
Biotechnology
Full-Time Employees
274